Human Genome Epidemiology Literature Finder
|
Records 1 - 16 (of 16 Records) |
| Query Trace: Ovarian Neoplasms and CYP3A4[original query] |
|---|
| The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002 Jul 12 (5): 355-66. Spurdle Amanda B, Goodwin Bryan, Hodgson Ecushla, Hopper John L, Chen Xiaoqing, Purdie David M, McCredie Margaret R E, Giles Graham G, Chenevix-Trench Georgia, Liddle Christoph |
| Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. Journal of clinical pharmacology 2005 Jun 45 (6): 674-82. Nakajima Miki, Fujiki Yuto, Kyo Satoru, Kanaya Taro, Nakamura Mitsuhiro, Maida Yoshiko, Tanaka Masaaki, Inoue Masaki, Yokoi Tsuyos |
| Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Oct 25 (29): 4528-35. Marsh Sharon, Paul Jim, King Cristi R, Gifford Gillian, McLeod Howard L, Brown Robe |
| Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007 Jan 16 (1): 165-8. Berndt Sonja I, Chatterjee Nilanjan, Huang Wen-Yi, Chanock Stephen J, Welch Robert, Crawford E David, Hayes Richard |
| Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Mar 26 (7): 1119-27. Rudin Charles M, Liu Wanqing, Desai Apurva, Karrison Theodore, Jiang Xuemin, Janisch Linda, Das Soma, Ramirez Jacqueline, Poonkuzhali Balasubramanian, Schuetz Erin, Fackenthal Donna Lee, Chen Peixian, Armstrong Deborah K, Brahmer Julie R, Fleming Gini F, Vokes Everett E, Carducci Michael A, Ratain Mark |
| Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. British journal of cancer 2009 Jan 100 (2): 412-20. Pearce C L, Near A M, Van Den Berg D J, Ramus S J, Gentry-Maharaj A, Menon U, Gayther S A, Anderson A R, Edlund C K, Wu A H, Chen X, Beesley J, Webb P M, Holt S K, Chen C, Doherty J A, Rossing M A, Whittemore A S, McGuire V, DiCioccio R A, Goodman M T, Lurie G, Carney M E, Wilkens L R, Ness R B, Moysich K B, Edwards R, Jennison E, Kjaer S K, Hogdall E, Hogdall C K, Goode E L, Sellers T A, Vierkant R A, Cunningham J M, Cunningham J C, Schildkraut J M, Berchuck A, Moorman P G, Iversen E S, Cramer D W, Terry K L, Vitonis A F, Titus-Ernstoff L, Song H, Pharoah P D P, Spurdle A B, Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V, Chenevix-Trench G, , |
| Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic & clinical pharmacology & toxicology 2009 Feb 104 (2): 130-7. Gréen Henrik, Söderkvist Peter, Rosenberg Per, Mirghani Rajaa A, Rymark Per, Lundqvist Elisabeth Avall, Peterson Cu |
| Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. International journal of molecular epidemiology and genetics 2011 2 (2): 185-95. Peethambaram Prema, Fridley Brooke L, Vierkant Robert A, Larson Melissa C, Kalli Kimberly R, Elliott Elaine A, Oberg Ann L, White Kristin L, Rider David N, Keeney Gary L, Cunningham Julie M, Hartmann Lynn C, Goode Ellen |
| Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European journal of clinical pharmacology 2011 Jul 67 (7): 693-700. Bergmann Troels K, Gréen Henrik, Brasch-Andersen Charlotte, Mirza Mansoor R, Herrstedt Jørn, Hølund Berit, du Bois Andreas, Damkier Per, Vach Werner, Brosen Kim, Peterson Cu |
| Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile. International journal of clinical and experimental medicine 2013 6 (7): 552-61. Assis Joana, Pereira Deolinda, Gomes Mónica, Marques Dânia, Marques Inês, Nogueira Augusto, Catarino Raquel, Medeiros R |
| Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC pharmacology & toxicology 2015 16 2. Lambrechts Sandrina, Lambrechts Diether, Despierre Evelyn, Van Nieuwenhuysen Els, Smeets Dominiek, Debruyne Philip R, Renard Vincent, Vroman Philippe, Luyten Daisy, Neven Patrick, Amant Frédéric, Leunen Karin, Vergote Ignace, |
| Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. Clinical therapeutics 2016 Oct . Dirix Luc, Swaisland Helen, Verheul Henk M W, Rottey Sylvie, Leunen Karin, Jerusalem Guy, Rolfo Christian, Nielsen Dorte, Molife L Rhoda, Kristeleit Rebecca, Vos-Geelen Judith de, Mau-Sørensen Morten, Soetekouw Patricia, van Herpen Carla, Fielding Anitra, So Karen, Bannister Wendy, Plummer Ru |
| Polymorphisms of ABCB1, CYP3A4 and CYP3A5 Genes in Ovarian Cancer and Treatment Response in Poles. Anticancer research 2018 03 38 (3): 1455-1459. Fiszer-Maliszewska ?ucja, ?aczma?ski ?ukasz, Doli?ska Aneta, Jagas Maria, Ko?odziejska Ewelina, Jankowska Magdalena, Ku?nierczyk Pio |
Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.
Cancer medicine 2019 Apr . Grant Delores J, Manichaikul Ani, Alberg Anthony J, Bandera Elisa V, Barnholtz-Sloan Jill, Bondy Melissa, Cote Michele L, Funkhouser Ellen, Moorman Patricia G, Peres Lauren C, Peters Edward S, Schwartz Ann G, Terry Paul D, Wang Xin-Qun, Keku Temitope O, Hoyo Cathrine, Berchuck Andrew, Sandler Dale P, Taylor Jack A, O'Brien Katie M, Velez Edwards Digna R, Edwards Todd L, Beeghly-Fadiel Alicia, Wentzensen Nicolas, Pearce Celeste Leigh, Wu Anna H, Whittemore Alice S, McGuire Valerie, Sieh Weiva, Rothstein Joseph H, Modugno Francesmary, Ness Roberta, Moysich Kirsten, Rossing Mary Anne, Doherty Jennifer A, Sellers Thomas A, Permuth-Way Jennifer B, Monteiro Alvaro N, Levine Douglas A, Setiawan Veronica Wendy, Haiman Christopher A, LeMarchand Loic, Wilkens Lynne R, Karlan Beth Y, Menon Usha, Ramus Susan, Gayther Simon, Gentry-Maharaj Aleksandra, Terry Kathryn L, Cramer Daniel W, Goode Ellen L, Larson Melissa C, Kaufmann Scott H, Cannioto Rikki, Odunsi Kunle, Etter John L, Huang Ruea-Yea, Bernardini Marcus Q, Tone Alicia A, May Taymaa, Goodman Marc T, Thompson Pamela J, Carney Michael E, Tworoger Shelley S, Poole Elizabeth M, Lambrechts Diether, Vergote Ignace, Vanderstichele Adriaan, Van Nieuwenhuysen Els, Anton-Culver Hoda, Ziogas Argyrios, Brenton James D, Bjorge Line, Salvensen Helga B, Kiemeney Lambertus A, Massuger Leon F A G, Pejovic Tanja, Bruegl Amanda, Moffitt Melissa, Cook Linda, Le Nhu D, Brooks-Wilson Angela, Kelemen Linda E, Pharoah Paul D P, Song Honglin, Campbell Ian, Eccles Diana, DeFazio Anna, Kennedy Catherine J, Schildkraut Joellen |
| A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. Journal of clinical pharmacology 2021 Apr . Stodtmann Sven, Nuthalapati Silpa, Eckert Doerthe, Kasichayanula Sreeneeranj, Joshi Rujuta, Bach Bruce A, Mensing Sven, Menon Rajeev, Xiong H |
| Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study. Gynecologic oncology 2024 5 187 139-144. M Zenatri, T Perennec, C Michon, F Gernier, J-M Grellard, F-X Piloquet, C Dubot-Poitelon, E Kalbacher, O Tredan, P Augereau, P Pautier, L Fey, F Joly, J-S Fren |
- Page last reviewed:Feb 1, 2024
- Content source: